Kun-Long Hung | Personalized Medicine | Top Pharmaceutical Breakthrough Discovery Award

Published on by Top Pharmaceutical

Top Pharmaceutical Breakthrough Discovery Award

Kun-Long Hung
Fu Jen Catholic University Hospital, Taiwan

Kun-Long Hung
Affiliation Fu Jen Catholic University Hospital
Country Taiwan
Scopus ID 7202728402
Documents 81
Citations 1,862
h-index 23
Subject Area Personalized Medicine
Event International Top Pharmaceutical Awards

Kun-Long Hung is a Taiwanese clinician and researcher associated with Fu Jen Catholic University Hospital. His scholarly record demonstrates sustained contributions to personalized medicine, pediatric neurology, genetic disorders, developmental diseases, and translational healthcare research. According to Scopus metrics, his publication portfolio includes more than eighty indexed documents and a substantial citation impact within the medical research community.[1]

Abstract

This article summarizes the academic profile and scientific achievements of Kun-Long Hung. His research activities have focused on personalized medicine approaches, pediatric neurological disorders, genetic diagnostics, and evidence-based clinical practice. Through multidisciplinary collaborations, he has contributed to improved understanding of rare diseases and patient-centered healthcare strategies.[1]

Keywords

Personalized Medicine, Pediatric Neurology, Genetic Disorders, Clinical Research, Rare Diseases, Translational Medicine, Precision Healthcare, Developmental Disorders, Neurogenetics, Medical Innovation.

Introduction

The advancement of personalized medicine depends on researchers who integrate clinical observations with scientific investigation. Kun-Long Hung has participated in studies addressing neurological and genetic conditions affecting children and families. His published work reflects an ongoing commitment to improving diagnostic accuracy and therapeutic decision-making in modern healthcare environments.[2]

Research Profile

Based in Taiwan, Hung has established a recognized publication record supported by 81 indexed documents, 1,862 citations, and an h-index of 23. His research portfolio spans neurodevelopmental disorders, pediatric epilepsy, genetic syndromes, and precision medicine applications. These metrics indicate consistent scholarly engagement and meaningful influence across multiple areas of clinical medicine.[1]

Research Contributions

Hung has contributed to investigations involving developmental delay, neurofibromatosis, Dravet syndrome, tubulinopathy, and other neurological disorders. His work frequently combines genetic evaluation with clinical assessment to support individualized treatment planning. Such contributions align closely with contemporary precision medicine objectives and patient-focused healthcare models.[3]

Publications

Among his notable publications are studies on neurofibromatosis management in Taiwan, neurological manifestations of SARS-CoV-2 infection in children, developmental delay diagnostics, and rare genetic disorders. These publications demonstrate continued participation in clinically relevant research that addresses both local and international healthcare challenges while supporting evidence-based practice.[2]

Research Impact

The citation performance associated with Hung’s publications reflects engagement from researchers across medical and scientific disciplines. His studies have contributed to discussions involving diagnosis, disease management, and long-term outcomes in pediatric populations. This influence supports continued visibility within international biomedical literature and healthcare research communities.[1]

Award Suitability

The International Top Pharmaceutical Awards recognize researchers whose work advances healthcare innovation and scientific understanding. Hung’s contributions to personalized medicine, combined with his publication record and citation impact, align with the objectives of recognizing meaningful research achievements. His work illustrates the integration of clinical expertise and translational investigation.[4]

Conclusion

Kun-Long Hung has developed a substantial academic profile through research focused on pediatric neurology, genetic medicine, and individualized healthcare. His scientific contributions, publication metrics, and collaborative activities demonstrate continued involvement in advancing medical knowledge. These achievements provide a strong foundation for recognition within international research and healthcare award programs.

References

  1. Elsevier. (n.d.). Scopus Author Profile: Hung, K. L. (Author ID: 7202728402). Scopus. https://www.scopus.com/authid/detail.uri?authorId=7202728402
  2. Chu, Y. J., Wong, L. C., Ho, C. S., Lee, W. T., & Hung, K. L. (2024). Neurological manifestations of SARS-CoV-2 infection in children in Taiwan: A cross-sectional multicenter study. Journal of the Formosan Medical Association. https://doi.org/10.1016/j.jfma.2024.01.001
  3. Huang, C. S., Hung, P. L., Fan, P. C., Lee, W. T., & Hung, K. L. (2021). Clinical spectrum and comorbidities of Dravet syndrome in Taiwan and possible molecular mechanisms. Scientific Reports, 11, Article 15092. https://pubmed.ncbi.nlm.nih.gov/34642351/
  4. Hung, K. L., Lu, J. F., Su, D., Hsu, S., & Wong, L. C. (2022). Tubulinopathy presenting as developmental and epileptic encephalopathy. Children, 9(11), 1663. https://doi.org/10.3390/children9111663
  5. Liang, J. S., Hung, K. L., Lin, L., Keng, W. T., & Lu, J. F. (2023). Novel PEX1 mutations in fibroblasts from children with Zellweger spectrum disorders exhibit temperature-sensitive characteristics. Epilepsy & Behavior, 147, 109387. https://doi.org/10.1016/j.yebeh.2023.109387

Olfa Trabelsi | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Women Researcher Award

Olfa Trabelsi
University of Technology of Compiègne, France

Olfa Trabelsi
Affiliation University of Technology of Compiègne
Country France
Scopus ID 36025990200
Documents 29
Citations 685
h-index 13
Subject Area Personalized Medicine
Event International Top Pharmaceutical Awards
ORCID 0000-0003-4415-8478

Olfa Trabelsi is a researcher affiliated with the University of Technology of Compiègne in France and is recognized for interdisciplinary research activities within biomedical engineering and personalized medicine. Her academic work combines computational mechanics with biological applications and demonstrates integration between engineering concepts and medical analysis. Bibliometric indicators and publication records indicate continuing contributions in tissue engineering and patient-specific modeling studies.[1]

Abstract

This article summarizes the academic profile and scientific contributions associated with Olfa Trabelsi. Research activities mainly involve computational biomechanics, tissue engineering applications, and biomedical modeling methodologies. Scientific outputs further indicate interdisciplinary collaborations designed to improve analytical approaches used in personalized medical systems and healthcare technologies.[2]

Keywords

Personalized Medicine, Biomedical Engineering, Biomechanics, Tissue Engineering, Computational Modeling, Medical Simulation, Patient-Specific Analysis.

Introduction

Current advances in healthcare increasingly rely on computational and patient-centered methodologies for diagnostic and therapeutic improvements. Olfa Trabelsi has participated in research environments involving biomedical analysis and engineering applications designed for clinical relevance. Such studies contribute toward the understanding of tissue behavior and individualized medical systems.[3]

Research Profile

According to ORCID records, Olfa Trabelsi currently serves as an Associate Professor at the University of Technology of Compiègne and has academic experience in biomechanics and computational mechanics research. Educational activities include doctoral studies in computational mechanics and multidisciplinary biomedical applications.[4]

Research Contributions

Research contributions include computational analysis of biological tissues, mechanical characterization studies, and predictive modeling techniques. Published investigations have focused on tracheal systems, vascular biomechanics, tissue remodeling processes, and personalized therapeutic assessment methods.[5]

Publications

Publication records demonstrate collaborative research across multiple biomedical disciplines and engineering frameworks. Scientific articles include computational bone remodeling studies, tissue engineering analysis, aneurysm prediction models, and tracheal mechanical simulations. Published works further illustrate integration between clinical requirements and engineering methodologies within patient-specific biomedical systems.

Research Impact

Citation statistics indicate measurable influence across scientific communities and interdisciplinary domains. The available bibliometric indicators suggest continuing relevance of published work and recognition through citations, collaborative outputs, and international dissemination activities.

Award Suitability

Academic metrics and scientific activities suggest alignment with criteria commonly associated with international research recognition programs. Contributions involving personalized medicine and biomedical technologies support consideration within broader scientific achievement categories.

Conclusion

Olfa Trabelsi represents an academic profile characterized by multidisciplinary investigation and continuing scientific activity. Research outputs demonstrate integration of engineering principles with healthcare technologies and support continuing development of personalized biomedical systems.

References

  1. Trabelsi, O., Duprey, A., Favre, J.P., & Avril, S. (2016). Predictive models with patient specific material properties for the biomechanical behavior of ascending thoracic aneurysms. Annals of Biomedical Engineering.
    https://doi.org/10.1007/s10439-015-1374-8
  2. Trabelsi, O., Davis, F.M., Rodriguez-Matas, J.F., Duprey, A., & Avril, S. (2015). Patient specific stress and rupture analysis of ascending thoracic aneurysms. Journal of Biomechanics.
    https://doi.org/10.1016/j.jbiomech.2015.04.035
  3. Trabelsi, O., et al. (2022). A simple and effective 1D-element discrete-based method for computational bone remodeling. Computer Methods in Biomechanics and Biomedical Engineering.
    https://doi.org/10.1080/10255842.2021.1943370
  4. Trabelsi, O., et al. (2020). In vitro histomechanical effects of enzymatic degradation in carotid arteries during inflation tests with pulsatile loading. Journal of Mechanical Behavior of Biomedical Materials.
    https://doi.org/10.1016/j.jmbbm.2019.103550
  5. Ruben, R.B., Carvalho, M., & Trabelsi, O. (2026). Biomechanics Analysis in Tissue Engineering. Bioengineering.
    https://doi.org/10.3390/bioengineering13060703

Maria Garrido | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Dr. Maria Garrido | Personalized Medicine | Women Researcher Award

Doctor at Hospital Universidtario 12 de octubre-Universidad Complutense de Madrid | Spain

Dr. Maria Garrido is a physician-scientist specializing in pathology and translational oncology with a focus on melanoma and cutaneous lymphomas. She earned her medical degree from the University of Granada and her PhD in Health Sciences and Biomedicine from Universidad Complutense de Madrid. With extensive international experience at the University of California San Francisco and Memorial Sloan Kettering, her research has contributed to landmark discoveries in oncogenes, fusion kinases, and tumor biomarkers. She currently works in dermatopathology and oncology research, collaborating with leading groups in Europe and internationally to advance personalized cancer diagnostics and therapeutic strategies.

Publication Profile 

Orcid

Education 

Dr. Maria Garrido obtained her medical degree in Medicine and Surgery from the University of Granada. She pursued her residency in Anatomical Pathology at Hospital Universitario 12 de Octubre, Madrid, and later completed a PhD in Health Sciences and Biomedicine at Universidad Complutense de Madrid. Complementing her medical and scientific training, she earned a Master’s in Clinical Management, Medical, and Healthcare Leadership from Universidad Tecnológica. Her academic formation integrates rigorous clinical foundations with molecular oncology research, allowing her to bridge patient care and translational science. She has continued to enhance her expertise through national and international academic fellowships.

Experience 

Dr. Maria Garrido has served as a resident and clinical specialist in pathology at major Spanish hospitals, including Hospital 12 de Octubre, Hospital General de Móstoles, and Clinic Hospital of Barcelona. Internationally, she was a fellowship researcher at UCSF and Memorial Sloan Kettering, contributing to melanoma genetics and translational oncology. She has collaborated on groundbreaking discoveries, including oncogenes in uveal melanoma and fusion kinases in Spitz tumors. Currently, she is part of the dermatopathology and oncology research group at Hospital Universitario 12 de Octubre, Madrid, where she advances studies on melanoma, lymphomas, molecular biomarkers, and diagnostic innovations in cutaneous oncology.

Awards and Honors 

Dr. Maria Garrido has received notable recognition for her research contributions. She was awarded a mobility fellowship by the Spanish Ministry of Science and Innovation for professional development in computational pathology at Queen’s University, Belfast. Her discoveries, including the GNA11 oncogene and fusion kinases in melanocytic tumors, have been published in high-impact journals such as the New England Journal of Medicine, Nature Communications, and Nature Genetics. Her contributions to the field of melanoma genetics have been cited worldwide, shaping the understanding of tumor biology. She continues to be honored through invitations to collaborate on international research initiatives and networks.

Research Focus 

Dr. Maria Garrido research focuses on the molecular pathology of melanoma and cutaneous lymphomas. She has made significant contributions to identifying oncogenes such as GNA11 and GNAQ, which account for most uveal melanomas, and discovering kinase fusion proteins in Spitz tumors. Her work also includes genetic studies on desmoplastic melanoma highlighting NFKBIE mutations. More recently, she has contributed to refining the classification of cutaneous lymphomas and identifying new biomarkers to guide diagnosis, prognosis, and therapeutic response. Her approach integrates pathology, molecular biology, and translational medicine to improve personalized treatment strategies and enhance patient outcomes in oncology and dermatopathology.

Publication Top Notes

Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances

Acute sarcoidosis as a harbinger for pancreatic adenocarcinoma

TERT promoter mutation in sebaceous neoplasms

Orbital Solitary Fibrous Tumor: Four Case Reports—Clinical and Histopathological Features

Conjunctival Tarsal Actinic Keratosis Treated with Interferon Alfa-2b: A Rare Case Report and Literature Review

SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases

Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma